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1. Introduction 
Chronic granulomatous disease (CGD) is an inherited disorder of the innate immune system 
characterized by impairment of intracellular microbicidal activity of phagocytes. Mutations 
in one of four known nicotinamide adenine dinucleotide phosphate (NADPH) -oxidase 
components preclude generation of superoxide and related antimicrobial oxidants, leading 
to the phenotype of CGD. Defects in gp91-phox, encoded by CYBB gene, lead to X-linked 
CGD and have been reported to be responsible for approximately 65% of all CGD cases. The 
autosomal gene in CGD are CYBA, encoding p22-phox, NCF2, encoding p67-phox, NCF1, 
encoding p47-phox, and NCF4, encoding p40-phox (figure 1) (1,2). The mutation in these 
genes, respectively, abolishes the activity of the oxidase and leads to autosomal recessive 
chronic granulomatous disease (AR-CGD) which is approximately 35% of all CGD cases 
(table 1).  
2. Phenotype- genotype correlation in CGD 
Identification of specific mutations in CGD patients may help to clarify some of the 
variability in clinical severity seen in this disorder and shows genotype-phenotype 
correlation. In general, X-CGD patients follow a more severe clinical course than patients 
with an AR-CGD and exhibit in the first years of life. AR-CGD patients follow a milder 
clinical course, especially p47-phox defect, and mostly seen in first and second decade of 
life. AR-CGD patients with missense mutations usually exhibit a mild clinical course, 
associated with a residual activity of p47-phox and also p22 and p67-phoxs. However, the 
level of superoxide generation does not always correlate with the clinical course. Some 
patients suffer from severe and recurrent infections despite having neutrophils with 10–20% 
of normal oxidase activity (1). Within our study with 40 AR-CGD families, we could not 
define a direct correlation between the molecular defect and the clinical course of the 
disease. Either truncations (nonsense and frameshift mutations) or missense mutations 
could have resulted in severe influence on phenotype.  
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Figure 1. NADPH oxidase enzyme subunits and complex in activation phase. 
 
Components gp91 phox p22 phox p47 phox p67 phox 
Gene CYBB CYBA NCF1 NCF2 
Chromosome Xp21.1 16q24 7q11.23 1q25 
Number of Exon 13 6 11 16 
The length of bp 30kb 8.5kb 15.3kb 40kb 
Genotype X91, X-linked R A22, OR A47, OR A67, OR 
Incidence % %60 %5 %30 %5 
The length of aa. chain 570 195 390 526 
Localization membrane membrane cytosol cytosol 
Table 1. The molecular characteristic of NADPH Oxidase components. 
3. CYBA (cytochrome b alfa chain) gene  
Cytochrome b is comprised of a light a-chain and a heavy b-chain. This gene encodes the 
light, alpha subunit which has been proposed as a primary component of the microbicidal 
oxidase system of phagocytes. Mutations in this gene are associated with AR-CGD that is 
characterized by the failure of activated phagocytes to generate superoxide, which is 
important for the microbicidal activity of these cells. http://www.genecards.org/cgi-
bin/carddisp.plgene=CYBA. 
In about 5% of the CGD patients, the disease is caused by mutations in the cytochrome b alfa 
chain (CYBA) gene. The CYBA gene encoding p22-phox which contains 195 amino acid, is 
localized on chromosome 16q24, has a size of about 8,5 and contains six exons and trans-
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membrane and proline rich domains [3, 4]. CYBA gene encoding p22-phox has 19 different 
missense mutations in 65 mutated alleles and has more missense mutation than other 
NADPH oxidase subunit genes (table 2a) (figure 2). Mutations in the CYBA gene have been 
updated by [Roos et al., (2)] and are reviewed in Human Gene Mutation Database, (HGMD; 
http://www.hgmd.cf.ac.uk/ac/all.php). 
P22-phox has a key role in the interaction of NADPH-oxidase subunits and any difference in 
amino acid pattern of this phox protein may change the globular conformation of this 
protein due to the difference in the electrophoretic characteristic of new amino acid, which 
prevents the complex formation with other subunits. 
 
Figure 2. Missense mutations in CYBA gene, encoding p22-phox; CYBA gene contains 6 exons. P22-
phox contains trans-membrane and proline rich domains. Missense mutation points in CYBA gene and 
change in encoded 195 aa. of p22-phox represented in the figure (2). 
Missense mutation points may have an important role in the interaction with other subunits, 
so the amino acid change in that regions may change the property of interactions and 
prevents or decreases  the complex formation, so the activity of NADPH oxidase was 
abolished. 
Total numbers of alleles which have missense mutations are 65 of 173 mutated alleles in 
CYBA gene and the percentage of missense mutations in that mutated alleles are %37,5 
(table 2a) (2). Percentage of missense and all mutations of CYBA gene in the overall 
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mutations of AR-CGD is %6.3 and %16.8, respectively (table 3 and 4). Most prevalent 
missense mutations points in CYBA gene are c.70G>A, c.268C>T and c.354C>A which cause 
p.Gly24Arg, p.Arg90Trp and p.Ser118Arg in p22-phox, respectively (table 5). 
4. NCF1 (Neutrophil Cytosolic Factor 1) gene 
In about 25% of the CGD patients, the disease is caused by mutations in the neutrophil 
cytosolic factor 1 (NCF1) gene on chromosome 7q11.23, which encodes p47phox, one of the 
structural components of the NADPH oxidase and has a size of about 40 kb and contains 11 
exons (5, 6). The protein encoded by this gene is a 47 kDa cytosolic subunit of neutrophil 
NADPH oxidase and is required for activation of the latent NADPH oxidase and contains 




Figure 3. Missense mutations in NCF1 gene, encoding p47-phox; NCF1 gene contains 11 exons. p47-
phox contains PX, SH3a, SH3b and polybasic domains. Mutation points in NCF1 gene and change in 
encoded 390 aa. of p47-phox represented in the figure (2). 
 A very common mutation found in these patients is a GT deletion in a GTGTrepeat 
sequence at the beginning of exon 2 of NCF1 (c.75_76delGT) gene (5, 7). NCF1 gene 
encoding p47-phox has only 4 different missense mutation in 6 alleles (table 2b) (figure 3) 
(2). P47-phox has an important role in the interaction of cytoplasmic NADPH-oxidase 
subunits and any difference in amino acid pattern of this phox protein may abolish the 
complex formation with other subunits. 
Total numbers of alleles which have missense mutations are 6 of 63 (other than delta-GT 
mutation in exon 2, in more than 620 alleles) mutated alleles in NCF1 gene and the 
percentage of missense mutations in that mutated alleles are %9,5. The percentage of 
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missense and all mutations (including delta-GT mutation) of NCF1 gene in the overall 
mutations of AR-CGD is %0.6 and %66.4, respectively (table 3 and 4). So, this high 
percentage due to the high number of delta-GT mutation in exon 2 of NCF1 gene and is 
more than all the mutations in AR-CGD (table 5). This deletion points is hot-spot mutation 
region for NCF1 gene.  
5. NCF2 (Neutrophil Cytosolic Factor 2) gene 
The neutrophil cytosolic factor 2 (NCF2) gene encoding p67-phox is localized on 
chromosome 1q25, has a size of about 40 kb and contains 16 exons and TRP1-4, AD, SH3a, 
PB1 and SH3b domains (figure 4) (7, 8). NCF2 gene, encoding p67-phox, has 41 different 
missense mutations in 171 mutated alleles (table 2c) (2, 4, 5, 6). Mutations in the NCF2 gene 
have been published by [Roos et al., (2)] and are reviewed in Human Gene Mutation 
Database, (HGMD; http://www.hgmd.cf.ac.uk/ac/all.php). P67-phox has a major role in the 
interaction of NADPH-oxidase subunits in cytoplasm and any difference in amino acid 






Figure 4. Missense mutations in NCF2 gene, encoding p67-phox; NCF2 gene contains 16 exons. P67-
phox contains TRP1-4, AD, SH3a, PB1 and SH3b domains. Mutation points in NCF2 gene and change in 
encoded 526 aa. of p67-phox represented in the figure (2). 
Total numbers of mutated alleles leading AR-CGD in NCF2 gene are 171 and 41 of them are 
missense and percentage of missense mutations in that mutated alleles are %24 (table 2c) (2). 
Percentage of missense and all mutations of NCF2 gene in the overall mutations of AR-CGD 
is %4 and %16.6, respectively (table 3 and 4). Most prevalent missense mutations points in 
NCF2 gene is c.279C>G which causes p.Asp93Glu in p67-phox (table 5).   
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Nucleotide change Amino acid change Amino acid # of families (alleles) 
c.2T>A p.Met1Lys M1K 1(2) 
c.70G>A p.Gly24Arg G24R 9(14) 
c.71G>A p.Gly24Glu G24E 1(2) 
c.74G>T p.Gly25Val G25V 1(1) 
c.152T>A p.Leu51Gln L51Q 1(1) 
c.155T>C p.Leu52Pro L52P 1(2) 
c.158A>T p.Glu53Val E53V 1(1) 
c.164C>G p.Pro55Arg Q55R 1(2) 
c.268C>T p.Arg90Trp R90W 8(14) 
c.268C>G p.Arg90Gly R90G 1(2) 
c.269G>A p.Arg90Gln R90Q 2(3) 
c.269G>C p.Arg90Pro R90P 1(2) 
c.281A>G p.His94Arg H94R 1(2) 
c.354C>A p.Ser118Arg S118R 4(8) 
c.370G>T p.Ala124Ser A124S 1(2) 
c.371C>T p.Ala124Val A124V 1(1) 
c.373G>A p.Ala125Thr A125T 1(2) 
c.385G>A p.Glu129Lys E129K 1(2) 
c.467C>A p.Pro156Gln P156Q 1(2) 
19 different alleles   65 alleles 
(a) 
Nucleotide change Amino acid change Amino acid # of families (alleles) 
c.125G>A p.Arg42Gln R42Q 3(3) 
c.730G>A p.Glu244Lys E244K 1(1) 
c.784G>A p.Gly262Ser G262S 1(1) 
c.789G>C p.Trp263Cys W263C 1(1) 
4 different alleles   6 alleles 
(b) 
Nucleotide change Amino acid change Amino acid # of families (alleles) 
c.1A>G p.Met1Val M1V 1(1) 
c.125A>G p.Asn42Ser N42S 1(2) 
c.130G>C p.Gly44Arg G44R 2(4) 
c.130G>T p.Gly44Cys G44C 1(2) 
c.230G>A p.Arg77Gln R77Q 3(3) 
c.233G>A p.Gly78Glu G78E 1(2) 
c.279C>G p.Asp93Glu D93E 4(8) 
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c.305G>C p.Arg102Pro R102P 1(1) 
c.323A>T p.Asp108Val D108V 1(2) 
c.383C>T p.Ala128Val A128V 1(2) 
c.409T>A p.Trp137Arg W137R 1(2) 
c.419C>G p.Ala140Asp A140D 1(1) 
c.[479A>T; 481A>G] p.AspLys160_161ValGlu DK160_161VE 1(1) 
c.505C>G p.Gln169Glu Q169E 1(2) 
c.551G>C p.Arg184Pro R184P 1(2) 
c.605C>T p.Ala202Val A202V 2(4) 
c.1256A>T p.Asn419Ile N419I 1(2) 
17 different alleles   41 alleles 
(c) 
Table 2. (a) Missense Mutation in CYBA gene. (b) Missense Mutation in NCF1 gene. (c) Missense 








In the all mutations of AR-
CGD 





CYBA 65 37,5 173 100 6.3 16.8 
NCF1 6 9,5* 63 +620* 100 0.6 66.4 
NCF2 41 24 171 100 4 16.6 
NCF4 1 50 2 100 0.1 0.2 
In AR-CGD 113 27.6 409+620* 100 11 100 
*: (delta-GT mutations in exon 2, not included) 
&: Including nonsense, missense, splice site, deletion and others. 
Table 3. Distribution of number and percentage of missense and all mutations in genes (CYBA, NCF1, 




# of different 
missense mutations
Total # of different 
mutations& 
Different missense / different 
all  mutations in that gene 
CYBA 19 55 %34.6 
NCF1 4 23 %17.4 
NCF2 17 54 %31.5 
NCF4 1 2 %50 
In AR-CGD 41 134 %30 
Table 4. Number and percentage of different missense mutations in genes (CYBA, NCF1, NCF2 and 
NCF4) of AR-CGD. 
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Autosomal Gene Nucleotide change Aa change Number of family (alleles) 
CYBA c.70G>A p.Gly24Arg 9(14) 
“ c.268C>T p.Arg90Trp 8(14) 
“ c.354C>A p.Ser118Arg 4(8) 
NCF1 c.125G>A p.Arg42Gln 3(3) 
NCF2 c.279C>G p.Asp93Glu 4(8) 
 
Table 5. Most prevalent missense mutation in the genes of AR-CGD. 
6. NCF4 (Neutrophil Cytosolic Factor 2) gene 
NCF4 gene encoding p40-phox with 339 amino acids is localized on chromosome 22q13.1 
has a size of about 4,4 kb and contains 10 exons. P40-phox interacts primarily with p67-
phox. Up to know, the first mutation in NCF4 gene was founded in a family with compound 
heterozygote mutations and one of the mutations was a missense with c.314G>A in one 
allele, which causes change in p.Arg105Gln amino acid in the structure of p40-phox (2, 9). 
7. Conclusion 
19 different alleles in CYBA gene, 4 different alleles in NCF1 gene, 17 different alleles in 
NCF2 gene and one allele in NCF4 gene have missense mutations which cause change in 
amino acid patterns of NADPH oxidase subunits and results in AR-CGD. The percentage of 
missense mutations in the overall mutations of AR-CGD is %11 (table 3). One of the most 
prevalent missense mutations in AR-CGD is in CYBA gene with c.70G>A, in 14 alleles of 9 
families, which causes p.Gly24Arg in p22-phox (table 5). 
In p22-phox the first interaction with p67-phox occur in B part (domain) which is located 
between 81-91 amino acids in p22-phox. There are 4 different missense mutations (in 21 
alleles of CYBA gene) change amino acid (arginine) at position 90. So, this position is highly 
susceptible to any conformational changes which may prevent the interaction with p67-
phox. So, the change in the molecular structure of this part may abolish the stability and 
function of p22-phox and latent NADPH oxidase could not be activated leading to AR-CGD. 
P22-phox has more different missense mutation than other NADPH oxidase components. 
The ratio of the number of different missense mutation and the number of amino acid in the 
chain is approximately 19/195 (%9.74). The different missense mutation to overall amino 
acid chain length in p67-phox is 17/526 (%3.23). But, the ratio in p47-phox is 4/390 (%1). This 
result shows that p67-phox has 3 times and p22-phox has approximately 10 times high 
incidence of different missense mutations than p47-phox in their primary amino acid 
structure. The underlying reason for this may be the highly specific interaction and function 
of p22-phox which is vulnerable to any change in the globular structure of protein. 
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